早期毒性測試市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、應用、最終用戶、地區和競爭格局分類，2021-2031年）

全球早期毒性測試市場預計將從 2025 年的 13.2 億美元成長到 2031 年的 19.9 億美元，複合年成長率為 7.08%。

該領域涉及在藥物發現早期階段進行的分析性安全性評估，旨在臨床試驗前識別藥物對生物系統的潛在不良反應。推動此領域發展的主要因素是：降低後期研發階段高失敗率的壓力日益增大，以及透過早期發現安全問題的候選藥物來最佳化研發預算的需求。根據歐洲製藥工業協會聯合會 (EFPIA) 的一份報告，到 2024 年，歐洲製藥業將在研發方面投入約 550 億歐元，這表明，為了避免代價高昂的研發失敗，必須進行嚴格的早期安全性評估，這其中涉及巨大的經濟利益。

然而，將臨床前數據準確轉化為人體生物學反應所面臨的生理挑戰阻礙了市場擴張。試管內和動物模型結果與臨床結果之間持續存在的差異造成了科學上的不確定性，並使新測試平台的檢驗過程變得複雜。這種差異減緩了整個產業對新型調查方法的採用。相關人員正努力確保早期研究結果能夠可靠地預測人體安全性。

市場促進因素

高通量篩檢和人工智慧在毒理學領域的融合，正從根本上改變市場格局，顯著提升預測準確性並縮短研發週期。借助計算模型和自動化平台，製藥公司能夠比傳統濕實驗室方法更快地從龐大的化合物庫中檢測出潛在的安全風險。這項技術變革直接滿足了在早期先導化合物發現階段識別毒理學風險的需求，從而最大限度地減少後期研發失敗，並簡化藥物研發流程。例如，2024年1月，Isomorphic Labs宣布與禮來公司達成策略合作，並獲得4,500萬美元的預付款，用於收購其用於小分子設計的AI平台。這顯示業界強烈希望採用In Silico調查方法來最佳化藥物的安全性和有效性分析。

此外，製藥業研發支出的不斷成長是進行嚴格的早期安全性評估的關鍵經濟促進因素。新療法上市成本的不斷攀升迫使企業採取嚴格的早期篩選策略，確保只有最有希望的候選藥物才能進入成本高昂的臨床試驗階段。根據羅氏於2024年2月發布的2023年度報告，該集團的研發支出總額將達到132億瑞士法郎，這反映出其在創新方面的大量投資，而這些創新需要透過有效的毒性篩檢來加以保護。同時，需要評估的候選藥物數量也持續增加。 2024年，美國食品藥物管理局（FDA）報告稱，與上年度相比，核准了55種新的分子實體，這凸顯了透過擴充性且可靠的毒性測試解決方案來實現永續生產力的必要性。

市場挑戰

將臨床前數據準確轉化為人體生物反應的生理複雜性，對全球早期毒性測試市場構成了重大障礙。核心問題在於現有體外和動物模型的預測能力有限，它們往往無法複製人體內複雜的毒性通路，從而造成科學空白，導致假陰性結果（即早期測試中被認為安全的化合物，在人體試驗中卻表現出嚴重的毒性）。因此，製藥公司對採用新的早期毒性測試平台仍持謹慎態度，擔心這些工具可能無法充分降低其產品組合的風險。

業界驚人的藥物研發失敗率進一步加劇了這種猶豫不決，凸顯了現有預測措施的不足。根據歐洲製藥工業協會聯合會（EFPIA）2024年的數據，平均而言，實驗室合成的每10,000種物質中，只有1-2種能夠最終完成所有研發階段，成為可上市藥物。如此低的成功率表明，儘管在早期安全性評估方面投入了大量資金，但早期檢測結果與臨床結果之間的相關性仍然很弱。這種不確定性迫使藥物研發人員繼續沿用冗長的測試通訊協定，而不是全面轉向創新的早期毒性解決方案，最終減緩了市場的整體成長速度。

市場趨勢

隨著業界努力克服傳統動物模型預測能力的局限性，晶片器官技術和微生理系統的應用正在迅速擴展。這些先進的微流體平台能夠精確模擬人體組織結構和流體動力學，從而在生理相關環境中實現化合物的高通量篩檢。這項轉變對於在開發平臺識別安全問題至關重要，並有助於減少對無法模擬人體系統反應的低保真度檢測方法的依賴。例如，2025年1月，MIMETAS公司發布了其重力驅動的無泵浦系統OrganoPlate UniFlow Technology，該系統在單一裝置中最多可支援512個晶片，展現了工業整合所需的擴充性。

同時，個人化毒性分析方法的出現正在從根本上重塑安全性評估，將重點從通用生物模型轉移到患者特異性評估。透過利用源自遺傳多樣性供體的人類誘導多能幹細胞（iPSCs），研究人員現在可以建立「晶片上的群體」面板，以檢測由個體間差異驅動的特異性藥物不良反應。這種方法滿足了識別標準臨床前研究中經常被忽略的脆弱亞群的關鍵需求，從而降低了臨床試驗意外失敗的風險。 2024年11月，Insphero宣布將主導一個價值6,800萬歐元的聯盟，致力於將特異性反映人類種族、年齡和性別多樣性的晶片器官系統產業化。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球早期毒性測試市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（體外、體內、In Silico）
  • 按應用領域（藥品、化妝品和個人護理用品、化學品和殺蟲劑、食品和飲料、環境毒理學、其他）
  • 按最終用戶分類（製藥和生物技術公司、學術和研究機構、政府和監管機構、化妝品和個人護理用品製造商、化學品製造商、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美早期毒理學檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲早期毒理學檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區早期毒性測試市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲早期毒理學檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲早期毒理學檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球早期毒理學檢測市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Eurofins Scientific Limited
• PerkinElmer, Inc.
• Merck KGaA
• WuXi AppTec
• Becton, Dickinson and Company
• Syngene International Limited
• Quest Diagnostics Incorporated

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Early Toxicity Testing Market is projected to expand from USD 1.32 Billion in 2025 to USD 1.99 Billion by 2031, reflecting a CAGR of 7.08%. This sector encompasses analytical safety assessments performed during the initial phases of drug discovery to identify potential adverse effects on biological systems prior to clinical trials. Growth is primarily driven by the intensifying pressure to reduce high attrition rates in late-stage development and the necessity to optimize research budgets by detecting unsafe candidates sooner. As reported by the European Federation of Pharmaceutical Industries and Associations, the pharmaceutical industry invested approximately 55 billion euros in research and development in Europe in 2024, underscoring the significant financial stakes that require rigorous early-stage safety profiling to mitigate expensive failures.

However, market expansion is hindered by the physiological difficulty of accurately translating preclinical data into human biological responses. The persistent gap between results derived from in vitro or animal models and actual clinical outcomes creates scientific uncertainty, which complicates the validation process for new testing platforms. This discrepancy slows the broad adoption of novel methodologies across the industry, as stakeholders grapple with the challenge of ensuring that early-stage findings reliably predict human safety profiles.

Market Driver

The integration of high-throughput screening and artificial intelligence into toxicology is fundamentally transforming the market by improving predictive accuracy and accelerating development timelines. By utilizing computational models and automated platforms, pharmaceutical companies can detect potential safety liabilities within vast compound libraries much faster than through traditional wet-lab methods. This technological shift directly addresses the need to minimize late-stage failures by identifying toxicological risks during the initial hit identification phase, thereby streamlining the drug discovery pipeline. For instance, Isomorphic Labs announced a strategic partnership with Eli Lilly and Company in January 2024, securing a $45 million upfront payment to deploy its AI platform for small molecule design, signaling a strong industrial commitment to adopting in silico methodologies for optimized safety and efficacy profiling.

Furthermore, rising research and development expenditures in the pharmaceutical sector act as a critical economic catalyst for implementing rigorous early-stage safety assessments. As the cost of bringing new therapies to market increases, companies are compelled to adopt strict early attrition strategies to ensure that only the most viable candidates advance to expensive clinical phases. According to Roche's 2023 Annual Report released in February 2024, the group incurred R&D expenses totaling 13.2 billion CHF, reflecting the immense capital dedicated to innovation that necessitates protection through effective toxicity screening. The volume of candidates requiring assessment continues to grow alongside these investments; the U.S. Food and Drug Administration reported the approval of 55 novel molecular entities in 2024 for the preceding year, highlighting sustained productivity that demands scalable and reliable toxicity testing solutions.

Market Challenge

The physiological complexity involved in accurately translating preclinical data to human biological responses constitutes a formidable barrier to the Global Early Toxicity Testing Market. The core issue stems from the limited predictive power of existing in vitro and animal models, which frequently fail to replicate the intricate toxicological pathways found in the human body. This scientific discrepancy leads to false negatives, where compounds appear safe in early testing but exhibit severe toxicity when administered to human subjects. Consequently, pharmaceutical organizations remain cautious about integrating novel early toxicity testing platforms, fearing that these tools may not sufficiently de-risk their portfolios.

This hesitation is reinforced by the staggering attrition rates observed in the industry, which underscore the inadequacy of current predictive measures. According to the European Federation of Pharmaceutical Industries and Associations in 2024, on average, only one to two of every 10,000 substances synthesized in laboratories successfully passed all development stages to become a marketable medicine. This extremely low success rate suggests that despite investments in early safety profiling, the correlation between early assays and clinical outcomes remains weak. This uncertainty forces drug developers to maintain redundant testing protocols rather than fully transitioning to innovative early toxicity solutions, thereby decelerating the market's overall growth trajectory.

Market Trends

The widespread adoption of Organ-on-a-Chip and Microphysiological Systems is rapidly accelerating as the industry strives to overcome the predictive limitations of traditional animal models. These advanced microfluidic platforms allow for the precise recapitulation of human tissue architecture and fluid dynamics, enabling high-throughput screening of compounds in a physiologically relevant environment. This transition is critical for identifying safety liabilities earlier in the pipeline, reducing reliance on low-fidelity assays that fail to mimic systemic human responses. For example, in January 2025, MIMETAS announced the launch of its OrganoPlate UniFlow Technology, a gravity-driven pumpless system capable of supporting up to 512 chips in a single setup, demonstrating the scalability required for industrial integration.

Concurrently, the emergence of personalized toxicity profiling approaches is fundamentally reshaping safety assessment by shifting focus from generic biological models to patient-specific evaluations. By utilizing human Induced Pluripotent Stem Cells (iPSCs) derived from genetically diverse donors, researchers can now construct "population-on-a-chip" panels that detect idiosyncratic adverse drug reactions caused by inter-individual variability. This approach addresses the critical need to identify vulnerable subpopulations that standard preclinical tests often miss, thereby mitigating the risk of unexpected clinical failures. In November 2024, InSphero announced that it is leading a consortium with a €68 million budget to industrialize organ-on-chip systems that specifically reflect human diversity in race, age, and gender.

Key Market Players

• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Eurofins Scientific Limited
• PerkinElmer, Inc.
• Merck KGaA
• WuXi AppTec
• Becton, Dickinson and Company
• Syngene International Limited
• Quest Diagnostics Incorporated

Report Scope

In this report, the Global Early Toxicity Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Early Toxicity Testing Market, By Type

• In Vitro
• In Vivo
• In Silico

Early Toxicity Testing Market, By Application

• Pharmaceuticals
• Cosmetics and Personal Care
• Chemicals and Agrochemicals
• Food and Beverages
• Environmental Toxicology
• Others

Early Toxicity Testing Market, By End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Government and Regulatory Agencies
• Cosmetics and Personal Care Manufacturers
• Chemical Manufacturers
• Others

Early Toxicity Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Early Toxicity Testing Market.

Available Customizations:

Global Early Toxicity Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Early Toxicity Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (In Vitro, In Vivo, In Silico)
  • 5.2.2. By Application (Pharmaceuticals, Cosmetics and Personal Care, Chemicals and Agrochemicals, Food and Beverages, Environmental Toxicology, Others)
  • 5.2.3. By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Government and Regulatory Agencies, Cosmetics and Personal Care Manufacturers, Chemical Manufacturers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Early Toxicity Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Early Toxicity Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Early Toxicity Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Early Toxicity Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Early Toxicity Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Early Toxicity Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Early Toxicity Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Early Toxicity Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Early Toxicity Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Early Toxicity Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Early Toxicity Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Early Toxicity Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Early Toxicity Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Early Toxicity Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Early Toxicity Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Early Toxicity Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Early Toxicity Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Early Toxicity Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Early Toxicity Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Early Toxicity Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Early Toxicity Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Early Toxicity Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Early Toxicity Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Early Toxicity Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Early Toxicity Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Agilent Technologies, Inc.
• 15.3. Bio-Rad Laboratories, Inc.
• 15.4. Eurofins Scientific Limited
• 15.5. PerkinElmer, Inc.
• 15.6. Merck KGaA
• 15.7. WuXi AppTec
• 15.8. Becton, Dickinson and Company
• 15.9. Syngene International Limited
• 15.10. Quest Diagnostics Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer